Abstract
The purpose of this study was to investigate the ability of the antimalarial drug, Ro 42-1611 to block parasite mediated cytokine induction in vitro as well as cytoadherence of infected erythrocytes to melanoma cells in vitro. The biological activity of Ro 42-1611 was confirmed as it blocked Plasmodium falciparum growth in cultures. Ro 42-1611, had no major effect on TNF, IL-alpha or IL-6 cytokine release from mononuclear cells stimulated with malaria antigens or lipopolysaccharide and it did not affect cell viability. Ro 42-1611 only slightly suppressed cytoadherence of infected erythrocytes to melanoma cells. The therapeutic effect of To 42-1611 appears to be confined to its parasite killing activity.
MeSH terms
-
Adult
-
Animals
-
Antigens, Protozoan / pharmacology
-
Antimalarials / pharmacology*
-
Artemisinins*
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
-
Cell Adhesion / drug effects
-
Cell Survival / drug effects
-
Cell Survival / physiology
-
Chloroquine / pharmacology
-
Cytokines / biosynthesis*
-
Dose-Response Relationship, Drug
-
Enzyme-Linked Immunosorbent Assay
-
Erythrocytes / drug effects
-
Erythrocytes / parasitology
-
Humans
-
Immunoglobulin G
-
Interleukin-1 / biosynthesis
-
Interleukin-6 / biosynthesis
-
Lipopolysaccharides / pharmacology
-
Lymphocytes / cytology
-
Lymphocytes / immunology*
-
Lymphocytes / parasitology
-
Malaria, Falciparum / blood*
-
Malaria, Falciparum / immunology
-
Mefloquine / pharmacology
-
Melanoma
-
Plasmodium falciparum / drug effects
-
Plasmodium falciparum / immunology
-
Plasmodium falciparum / physiology*
-
Styrenes / pharmacology*
-
Tumor Cells, Cultured
-
Tumor Necrosis Factor-alpha / biosynthesis
Substances
-
Antigens, Protozoan
-
Antimalarials
-
Artemisinins
-
Bridged Bicyclo Compounds, Heterocyclic
-
Cytokines
-
Immunoglobulin G
-
Interleukin-1
-
Interleukin-6
-
Lipopolysaccharides
-
Styrenes
-
Tumor Necrosis Factor-alpha
-
arteflene
-
Chloroquine
-
Mefloquine